Article info
PDFGenetics
Paper
Personal utility in genomic testing: is there such a thing?
- Correspondence to Eline M Bunnik, Department of Medical Ethics and Philosophy of Medicine, Erasmus MC, University Medical Center Rotterdam, Room Na 21.02, PO Box 2400, Rotterdam 3000 CA, The Netherlands; e.bunnik{at}erasmusmc.nl
Citation
Personal utility in genomic testing: is there such a thing?
Publication history
- Received October 24, 2013
- Revised March 11, 2014
- Accepted April 30, 2014
- First published May 28, 2014.
Online issue publication
February 22, 2018
Article Versions
- Previous version (27 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Other content recommended for you
- On the personal utility of Alzheimer’s disease-related biomarker testing in the research context
- Personal utility is inherent to direct-to-consumer genomic testing
- A practical guide to interpretation and clinical application of personal genomic screening
- Guideline for feedback of individual genetic research findings for genomics research in Africa
- Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trial
- Impact of direct-to-consumer genomic testing at long term follow-up
- Defining and managing incidental findings in genetic and genomic practice
- Moral motivation regarding dementia risk testing among affected persons in Germany and Israel
- Clinical application of fetal genome-wide sequencing during pregnancy: position statement of the Canadian College of Medical Geneticists
- Direct-to-consumer pharmacogenomic testing is associated with increased physician utilisation